Global Rubella Diagnostic Testing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Testing Technique;

Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA), Fluorescent Immunoassay (FIA), and Others

By Application;

Hospitals, Laboratories, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn443538325 Published Date: June, 2025 Updated Date: July, 2025

Rubella Diagnostic Testing Market Overview

Rubella Diagnostic Testing Market (USD Million)

Rubella Diagnostic Testing Market was valued at USD 5,894.44 million in the year 2024. The size of this market is expected to increase to USD 8,021.52 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.5%.


Global Rubella Diagnostic Testing Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 4.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)4.5 %
Market Size (2024)USD 5,894.44 Million
Market Size (2031)USD 8,021.52 Million
Market ConcentrationHigh
Report Pages377
5,894.44
2024
8,021.52
2031

Major Players

  • Abbott
  • Beckman Coulter
  • Bio Rad Laboratories
  • Biokit SA
  • bioMrieux SA
  • F. Hoffmann-La Roche Ltd
  • Ortho Clinical Diagnostics
  • Siemens Healthcare GmbH

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Rubella Diagnostic Testing Market

Fragmented - Highly competitive market without dominant players


The Rubella Diagnostic Testing Market is witnessing strong progress driven by rising awareness in maternal health programs and expanding initiatives in public disease prevention. Over 66% of prenatal care centers have now adopted routine rubella screening protocols, significantly improving early detection accuracy. The growing implementation of automated diagnostic systems is accelerating growth, with increasing emphasis on preventive strategies. The market holds a promising future outlook as more healthcare providers upgrade to high-sensitivity solutions backed by robust infrastructure expansion.

Technological Advancements and Innovation
Approximately 59% of diagnostic labs are now equipped with molecular-based assays and automated platforms, enabling faster and more accurate rubella testing. The market is benefiting from rapid technological advancements, especially in sample-to-answer systems and digital connectivity. Companies are focusing on innovation by developing portable and real-time devices through intensive R&D efforts. These efforts are often supported by strategic partnerships and collaborations, strengthening the overall capability of the market.

Strategic Opportunities and Growth Initiatives
Nearly 63% of healthcare institutions are enhancing their diagnostic reach through standardized rubella screening protocols, opening substantial opportunities for tailored testing solutions. Companies are launching targeted strategies to serve high-risk populations and improve diagnostic availability. These initiatives are driving measurable growth while helping address unmet clinical needs. This upward momentum is being amplified by investments in training, usability, and workflow optimization to support widespread clinical adoption.

Future Outlook and Public–Private Partnerships
More than 61% of future diagnostic investments are expected to be driven by public–private collaborations focusing on infectious disease control. These initiatives are encouraging better reimbursement systems, infrastructure upgrades, and implementation of automated testing platforms. As industry stakeholders continue to prioritize innovation, the market is set to benefit from improved access, broader reach, and long-term growth. The strategic focus on future outlook, testing efficiency, and infrastructure resilience will play a key role in shaping the next phase of development.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Testing Technique
    2. Market Snapshot, By Application
    3. Market Snapshot, By Region
  4. Rubella Diagnostic Testing Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Incidence of Rubella Infections
        2. Government Initiatives for Disease Control
        3. Advancements in Diagnostic Technologies
        4. Growing Awareness about Rubella Vaccination
      2. Restraints
        1. Limited Access to Diagnostic Facilities
        2. High Cost of Diagnostic Tests
        3. Lack of Skilled Healthcare Personnel
        4. Stringent Regulatory Requirements
      3. Opportunities
        1. Development of Point-of-Care Testing
        2. Expansion into Emerging Markets
        3. Integration of Molecular Diagnostic Techniques
        4. Collaboration with Public Health Agencies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Rubella Diagnostic Testing Market, By Testing Technique, 2021 - 2031 (USD Million)
      1. Latex Agglutination
      2. Enzyme Immunoassay (EIA)
      3. Radioimmunoassay (RIA)
      4. Fluorescent Immunoassay (FIA)
      5. Others
    2. Rubella Diagnostic Testing Market, By Application, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Laboratories
      3. Others
    3. Rubella Diagnostic Testing Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott
      2. Beckman Coulter
      3. Bio Rad Laboratories
      4. Biokit SA
      5. bioMrieux SA
      6. F. Hoffmann-La Roche Ltd
      7. Ortho Clinical Diagnostics
      8. Siemens Healthcare GmbH
  7. Analyst Views
  8. Future Outlook of the Market